Osmotica Pharmaceuticals, develops and sells extended-release neurology and women's health drugs, announced terms for its IPO on Monday.
The Bridgewater, NJ-based company plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Osmotica Pharmaceuticals would command a fully diluted market value of $767 million.
Osmotica Pharmaceuticals was founded in 1986 and booked $262 million in sales for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol OSMT. Jefferies, Barclays, RBC Capital Markets and Wells Fargo Securities are the joint bookrunners on the deal. It is expected to price during the week of October 8, 2018.
